11/12
04:14 pm
nuvb
Nuvation Bio to Present at the Jefferies London Healthcare Conference [Yahoo! Finance]
Low
Report
Nuvation Bio to Present at the Jefferies London Healthcare Conference [Yahoo! Finance]
11/12
04:05 pm
nuvb
Nuvation Bio to Present at the Jefferies London Healthcare Conference
Low
Report
Nuvation Bio to Present at the Jefferies London Healthcare Conference
11/7
12:32 pm
nuvb
Nuvation Bio Inc. (NYSE: NUVB) had its price target raised by analysts at Royal Bank of Canada from $5.00 to $6.00. They now have an "outperform" rating on the stock.
Low
Report
Nuvation Bio Inc. (NYSE: NUVB) had its price target raised by analysts at Royal Bank of Canada from $5.00 to $6.00. They now have an "outperform" rating on the stock.
11/7
11:14 am
nuvb
Nuvation Bio Inc. (NYSE: NUVB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
Low
Report
Nuvation Bio Inc. (NYSE: NUVB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
11/6
04:05 pm
nuvb
Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
Low
Report
Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
11/6
01:21 am
nuvb
Nuvation Bio Inc. (NUVB): Promising Penny Stock with Strong Oncology Pipeline [Yahoo! Finance]
High
Report
Nuvation Bio Inc. (NUVB): Promising Penny Stock with Strong Oncology Pipeline [Yahoo! Finance]
10/22
11:39 am
nuvb
Nuvation Bio Inc. (NYSE: NUVB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
Low
Report
Nuvation Bio Inc. (NYSE: NUVB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
10/16
11:52 am
nuvb
Is Nuvation Bio Inc. (NUVB) the Hottest Penny Stock to Invest in According to Hedge Funds? [Yahoo! Finance]
Low
Report
Is Nuvation Bio Inc. (NUVB) the Hottest Penny Stock to Invest in According to Hedge Funds? [Yahoo! Finance]
10/16
07:51 am
nuvb
Robert Mashal At Nuvation Bio Tops Up Holding By US$220k [Yahoo! Finance]
Medium
Report
Robert Mashal At Nuvation Bio Tops Up Holding By US$220k [Yahoo! Finance]
10/7
04:32 pm
nuvb
Nuvation Bio names Philippe Sauvage CFO [Seeking Alpha]
Low
Report
Nuvation Bio names Philippe Sauvage CFO [Seeking Alpha]
10/7
04:05 pm
nuvb
Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer
Low
Report
Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer
9/16
08:03 am
nuvb
Nuvation Bio Inc. (NYSE: NUVB) had its price target lowered by analysts at HC Wainwright from $8.00 to $7.00. They now have a "buy" rating on the stock.
Low
Report
Nuvation Bio Inc. (NYSE: NUVB) had its price target lowered by analysts at HC Wainwright from $8.00 to $7.00. They now have a "buy" rating on the stock.
9/14
03:12 am
nuvb
Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 [Yah
Low
Report
Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 [Yah
9/14
03:05 am
nuvb
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
Low
Report
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
9/11
09:18 am
nuvb
Nuvation Bio Inc. (NYSE: NUVB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
Medium
Report
Nuvation Bio Inc. (NYSE: NUVB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
9/9
08:00 am
nuvb
Nuvation Bio to Present at the Cantor Global Healthcare Conference
Medium
Report
Nuvation Bio to Present at the Cantor Global Healthcare Conference
8/22
11:03 pm
nuvb
Nuvation Bio Inc. (NYSE: NUVB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
Low
Report
Nuvation Bio Inc. (NYSE: NUVB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.